Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia

Chondroitin sulfate proteoglycan 4 (CSPG4), a highly immunogenic melanoma tumor antigen, is a potential target for antibody-based immunotherapy. The mechanism by which CSPG4 affects melanoma progression is only partly understood, in particular the involvement of other receptor tyrosine kinases and t...

Descripción completa

Detalles Bibliográficos
Autores principales: PUCCIARELLI, DANIELA, LENGGER, NINA, TAKACOVA, MARTINA, CSADEROVA, LUCIA, BARTOSOVA, MARIA, BREITENEDER, HEIMO, PASTOREKOVA, SILVIA, HAFNER, CHRISTINE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485656/
https://www.ncbi.nlm.nih.gov/pubmed/25997619
http://dx.doi.org/10.3892/ijo.2015.3010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485656/
https://www.ncbi.nlm.nih.gov/pubmed/25997619
http://dx.doi.org/10.3892/ijo.2015.3010

Ejemplares similares